Fibrodysplasia Ossificans Progressiva clinical trials at UCSF
3 in progress, 2 open to eligible people
Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
open to eligible people ages 2 years and up
This study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP). The study will evaluate how safe and effective andecaliximab is in patients…
San Francisco, California and other locations
Observational Pre-post Study to Observe if the Off Label Use of Anti-IL1 Therapies, Such as Anakinra or Canakinumab, Can Block ACVR1-induced Flare Activity and Heterotopic Ossification in FOP
open to eligible people ages 6-17
This is an observational pre-post study to observe if the off label use of anti-IL1 therapies, such as anakinra or canakinumab, can block ACVR1-induced flare activity and heterotopic ossification in FOP. It will also generate key tools and…
San Francisco, California
2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).
Sorry, in progress, not accepting new patients
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by the presence of bone in soft tissue where bone normally does not exist, known as Heterotopic Ossification (HO). It is often associated with painful,…
San Francisco, California and other locations
Our lead scientists for Fibrodysplasia Ossificans Progressiva research studies include Edward Hsiao.
Last updated: